(Q41459549)

1 October 2017

1 reference

title

Nonresectional therapies for hepatocellular carcinoma (English)

1 reference

1 October 2017

Liu CL

1

1 reference

1 October 2017

Fan ST

series ordinal

2

1 reference

1 October 2017

language of work or name

English

0 references

publication date

1 April 1997

1 reference

The American Journal of Surgery

1 October 2017

published in

1 reference

1 October 2017

volume

173

1 reference

1 October 2017

issue

4

1 reference

1 October 2017

page(s)

358-365

1 reference

Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Hepatic resection for hepatocellular carcinoma. An audit of 343 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Primary liver cancer in Japan. Sixth report. The Liver Cancer Study Group of Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Hepatic resection for hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

The Potential Role of Postoperative Hepatic Artery Chemotherapy in Patients with High-risk Hepatomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Improved survival for hepatocellular cancer with combination surgery and multimodality treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Small hepatocellular carcinoma: treatment with US-guided intratumoral injection of acetic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Cryotherapy for liver metastases: a new approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Ultrasound-guided hepatic cryosurgery in the treatment of metastatic colon carcinoma. Preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A 5-Year Study of Cryosurgery in the Treatment of Liver Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Treatment of hepatic metastases by cryotherapy and regional cytotoxic perfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Treatment of hepatocellular carcinoma with adriamycin.Preliminary communication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Phase II study of oral VP-16-213 in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Primary liver cancer. An Eastern Cooperative Oncology Group Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Transcatheter oily chemoembolization of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Transcatheter arterial chemoembolization for hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Analysis of prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Hepatic artery embolization for inoperable hepatocellular carcinoma; prognosis and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Primary treatment of hepatocellular carcinoma by arterial chemoembolization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

The role of surgery in the management of unusual complications of transcatheter arterial embolization for hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Internal radiation therapy for hepatocellular carcinoma. Results of a french multicenter phase II trial of transarterial injection of iodine 131-labeled lipiodol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Hemodynamic effects of vasodilator therapy in severe left heart failure combined with large atrial septal defects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A phase II trial of tamoxifen in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Defective function of lymphokine-activated killer cells and natural killer cells in patients with hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Follow-up study of combination treatment (TAE and PEIT) for unresectable hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Transcatheter arterial embolization followed by percutaneous ethanol injection in the treatment of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Results of treatment of patients with hepatocellular carcinoma with severe cirrhosis of the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Resection of hepatocellular carcinoma after transcatheter arterial embolization. Reevaluation of the advantages and disadvantages of preoperative embolization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Primary hepatocellular carcinoma—etiology, pathogenesis, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

Intratumor ethanol injection therapy for solitary minute hepatocellular carcinoma. A study of 37 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2896%2900384-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9610(96)00384-4

1 reference

1 October 2017

1 reference